← All diseases Cancer

Prostate cancer (metastatic)

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchEvidence of the highest level only (137)Meta-analysis (28)Treatment guideline (1)Randomized trial (67)Phase 3 study (21)Systematic review (20)Clinical trial (627)Review article (238)Early study (phase 1 or 2) (44)Single patient description (132)Laboratory or animal study (27)Commentary or editorial (29)Retracted publication (3) Studies currently recruiting participants only (49)

Filter

Publications (1472)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatments. (2024/04/01) ♡
• A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation. (2024/03/22) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential. (2024/03/05) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Lipid metabolism, amino acid metabolism, and prostate cancer: a crucial metabolic journey. (2024/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Deregulated miRNAs in enzalutamide resistant prostate cancer: A comprehensive review of key molecular alterations and clinical outcomes. (2024/03/01) ♡
• Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study. (2024/03/01) ♡
• Surgical approach affecting long-term urinary continence status after robot-assisted laparoscopic prostatectomy prospectively evaluated using self-reported functional status (Expanded Prostate Cancer Index Composite, EPIC-26). (2024/03/01) ♡
• Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study. (2024/03/01) ♡
• Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study. (2024/03/01) ♡
• High-power holmium laser versus thulium fiber laser for endoscopic enucleation of the prostate in patients with glands larger than 80 ml: Results from the Prostate Endoscopic EnucLeation study group. (2024/03/01) ♡
• Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review. (2024/02/29) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Radiotherapy Metastatic Prostate Cancer Cell Lines Treated with Gold Nanorods Modulate miRNA Signatures. (2024/02/27) ♡
• Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer. (2024/02/21) ♡
• High-fat diet promotes prostate cancer metastasis via RPS27. (2024/02/16) ♡
• Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapy. (2024/02/02) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. 177 Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer. (2024/02/01) ♡
• Quality by design fostered fabrication of cabazitaxel loaded pH-responsive Improved nanotherapeutics against prostate cancer. (2024/02/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. (2024/02/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Effectiveness of a Nurse-Led Mobile-Based Health Coaching Program for Patients With Prostate Cancer at High Risk of Metabolic Syndrome: Randomized Waitlist Controlled Trial. (2024/02/01) ♡
• Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice. (2024/01/23) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case report: Robotically visualized and biopsy-confirmed peritoneal carcinomatosis as initial identification of metastatic prostate adenocarcinoma in a patient with a history of prostatic urethral lift. (2024/01/19) ♡
• Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer. (2024/01/09) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current status of PSMA-targeted imaging and therapy. (2024/01/09) ♡
• Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience. (2024/01/09) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Role of gonadotropin-releasing hormone 2 and its receptor in human reproductive cancers. (2024/01/08) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers. (2024/01/08) ♡
• Association of neighborhood gentrification with prostate cancer and immune markers in African American and European American men. (2024/01/01) ♡
• Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study. (2024/01/01) ♡
• Is rucaparib the definite direction for metastatic prostate cancer? - TRITON3 results decoded. (2024/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. (2024/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Targeting Androgen Receptor Mutations in Metastatic Castration-Resistant Prostate Cancer with a Novel Androgen Biosynthesis Inhibitor. (2024/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Statistics of Rare Events. (2024/01/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Vikil (20) Suppresses the Proliferation of Prostate Cancer (PC-3) Cells and Quenches Free Radicals In Vitro. (2024/01/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Staying Strong and Healthy During Androgen Deprivation Therapy. (2024/01/01) ♡
• Effect of food and polymorphisms in SLCO2B1, CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers. (2024/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Periprostatic Adipose Tissue: A New Perspective for Diagnosing and Treating Prostate Cancer. (2024/01/01) ♡
• [UPFRONT DOCETAXEL WITH ANDROGEN DEPRIVATION THERAPY IN MALES WITH HIGH-VOLUME METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: RESULTS OF A SINGLE-INSTITUTION SERIES]. (2024/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [A CASE OF SEVERE DRUG INDUCED ERUPTION AFTER APALUTAMIDE USE FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, WHICH WAS DETERIORATED FROM TEMPORARY REMISSION AFTER DRUG WITHDRAWAL]. (2024/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. The growing role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer. (2023/12/31) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. (2023/12/31) ♡
• Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer. (2023/12/30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood. (2023/12/30) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients. (2023/12/29) ♡
• Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [(68)Ga]Ga-RM2-A Head-to-Head Pilot Comparison with [(68)Ga]Ga-PSMA-11. (2023/12/29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Anti-Algics in the Therapeutic Response of Breast and Urological Cancers. (2023/12/29) ♡
• Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E(2)-RADIatE OligoCare cohort. (2023/12/29) ♡
• Metastatic Sites in Rare Genitourinary Malignancies and Primary Cancer Sites in Genitourinary Organ Metastases: A Secondary Analysis Using the Japanese Pathological Autopsy Registry Database. (2023/12/29) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Superscan on (68)Ga PSMA PET/CT in patients with metastatic prostate carcinoma: A case series. (2023/12/28) ♡
• National Burden and Trends for 29 Groups of Cancer in Mexico from 1990 to 2019: A Secondary Analysis of the Global Burden of Disease Study 2019. (2023/12/28) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical Biofluid Assays for Prostate Cancer. (2023/12/28) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.